AMGN
Amgen Inc.
Price performance
Sep 18, 2026About
Company activity
19 events| Time | Ticker | Type | Event | Qty | Price | Value |
|---|---|---|---|---|---|---|
| 08/04 | AMGN | 8-K | Amgen Reports Strong Second Quarter 2026 Financial Results and Product Performance | — | — | — |
| 07/31 | AMGN | 8-K | Amgen Inc. Discloses Material Cybersecurity Incident | — | — | — |
| 05/20 | AMGN | 8-K | Amgen Inc. Announces Results of Annual Meeting of Stockholders | — | — | — |
| 05/19 | AMGN | 8-K | Amgen Announces Retirement of CFO Peter Griffith and Appointment of Thomas Dittrich | — | — | — |
| 04/30 | AMGN | 8-K | Amgen Reports Strong First Quarter 2026 Financial Results with Revenue Growth and Product Sales Performance | — | — | — |
| 04/22 | AMGN | 8-K | Amgen Announces Retirement of Chief Technology Officer David M. Reese | — | — | — |
| 02/19 | AMGN | 8-K | Amgen Inc. Issued $4.0 Billion of Senior Notes | — | — | — |
| 02/03 | AMGN | 8-K | Amgen Discloses 2025 Earnings and Non-GAAP Financial Measures | — | — | — |
| 01/30 | AMGN | 8-K | Amgen Terminates License and Collaboration Agreement with Kyowa Kirin | — | — | — |
| 11/04/25 | AMGN | 8-K | Amgen Reports Strong Third Quarter 2025 Financial Results | — | — | — |
| 08/05/25 | AMGN | 8-K | Amgen Reports Strong Second Quarter 2025 Financial Results | — | — | — |
| 05/27/25 | AMGN | 8-K | Amgen Inc. Announces Voting Results from Annual Meeting of Stockholders | — | — | — |
| 05/01/25 | AMGN | 8-K | Amgen Reports Strong First Quarter 2025 Financial Results | — | — | — |
| 02/04/25 | AMGN | 8-K | Amgen Announces Fourth Quarter and Full Year 2024 Financial Results and Non-GAAP Measures | — | — | — |
| 10/30/24 | AMGN | 8-K | Amgen Reports Strong Third Quarter 2024 Financial Results | — | — | — |
| 08/06/24 | AMGN | 8-K | Amgen Announces Second Quarter 2024 Financial Results | — | — | — |
| 06/03/24 | AMGN | 8-K | Amgen Inc. Approves Equity Incentive Plan and Elects Directors | — | — | — |
| 05/02/24 | AMGN | 8-K | Amgen Reports First Quarter 2024 Financial Results | — | — | — |
| 02/06/24 | AMGN | 8-K | Amgen Announces Fourth Quarter 2023 Unaudited Financial Results | — | — | — |
AMGN filing record
Amgen Inc. (AMGN): 19 8-K filings summarized, the most recent on Aug 4, 2026.
What the 8-K filings said
- Aug 4, 2026 · medium impact
Amgen Inc. reported strong financial results for the second quarter of 2026, with total revenues increasing by 10% to $10.1 billion. GAAP earnings per share (EPS) increased by 65% to $4.37, driven by higher revenues. Non-GAAP EPS increased by 4% to $6.29. Product sales grew by 9%, with 22 products delivering at least…
Amgen Reports Strong Second Quarter 2026 Financial Results and Product Performance - Jul 31, 2026 · medium impact
In July 2026, Amgen Inc. identified unauthorized activity involving data stored in cloud environments hosted by third-party cloud service providers. The company has determined that some of its data, including proprietary data, patient protected health information, and other information, has been exfiltrated. Amgen has…
Amgen Inc. Discloses Material Cybersecurity Incident - May 20, 2026 · medium impact
Amgen Inc. held its Annual Meeting on May 19, 2026, where all 12 nominees for director were elected to serve a one-year term. The advisory vote to approve executive compensation was approved, and Ernst & Young LLP was ratified as the Company's independent registered public accountants for the fiscal year ending…
Amgen Inc. Announces Results of Annual Meeting of Stockholders - May 19, 2026 · high impact
On May 19, 2026, Amgen Inc. announced the retirement of Peter H. Griffith, its Executive Vice President and Chief Financial Officer, effective August 31, 2026. Griffith will remain with the company until January 2027 in a non-executive role to ensure a smooth transition. Thomas Dittrich has been appointed as…
Amgen Announces Retirement of CFO Peter Griffith and Appointment of Thomas Dittrich - Apr 30, 2026 · medium impact
Amgen announced its first quarter 2026 financial results, reporting a 6% increase in total revenues to $8.6 billion. Product sales grew 4%, driven by 9% volume growth, partially offset by lower net selling price and inventory levels. Sixteen products delivered at least double-digit sales growth, and seventeen products…
Amgen Reports Strong First Quarter 2026 Financial Results with Revenue Growth and Product Sales Performance
SEC filings in the last five years
- 47 Form 8-K
- 13 Form 10-Q
- 5 Form 10-K